More from Renaissance Capital
Referenced Stocks

Durata Therapeutics prices IPO at $9, below the range

By Renaissance Capital,  July 18, 2012, 07:32:41 PM EDT

Durata Therapeutics, which is developing a Phase 3 antibiotic candidate for acute skin infections, raised $68 million by offering 7.5 million shares at $9, below the range of $11 to $13. Because Durata had planned to offer only 6.3 million shares, the proceeds were just 9% less than expected. Durata Therapeutics plans to list on the NASDAQ under the symbol DRTX. BofA Merrill Lynch and Credit Suisse acted as lead managers on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.


This article appears in: News Headlines, IPOs

Referenced Stocks: DRTX



Latest News Video



Sign-in
Existing NASDAQ.com member? Log in here.

By signing into to the site using any of the third-party services above, you agree to NASDAQ.com's Terms of Use.

From Our Trusted News Source





Most Active by Volume:

Company Last Sale Change Net / %
BAC $ 13.31 0.13  0.97%
PFE $ 29.30 0.52  1.81%
GE $ 23.86 0.20  0.85%
F $ 14.97 0.02  0.13%
MSFT $ 34.61 0.24  0.69%
QQQ $ 73.65 0.62  0.83%
MU $ 10.92 0.31  2.76%
INTC $ 24.07 0.08  0.33%